(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 April 2023 (27.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/067051 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/18* (2006.01)
A61K 9/08 (2006.01) *A61K 47/26* (2006.01)

(21) International Application Number:
PCT/EP2022/079185

(22) International Filing Date:
20 October 2022 (20.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2115127.9 21 October 2021 (21.10.2021) GB

(71) Applicant: **UCB BIOPHARMA SRL** [BE/BE]; Allée de la Recherche, 60, B-1070 BRUSSELS (BE).

(72) Inventors: **MARQUETTE, Sarah**; c/o UCB BIOPHARMA SRL, Allée de la Recherche, 60, B-1070 BRUSSELS (BE). **PEERBOOM, Claude**; c/o UCB BIOPHARMA SRL, Allée de la Recherche, 60, B-1070 BRUSSELS (BE). **BOONEN, Michaël Joseph Edouard**; c/o UCB BIOPHARMA SRL, Allée de la Recherche, 60, B-1070 BRUSSELS (BE).

(74) Agent: **BERTUCCIO, Silvia**; c/o Bianchetti & Minoja Srl, Via Plinio, 63, 20129 MILANO (IT).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: FORMULATIONS

(57) Abstract: The invention relates to the field of pharmaceutical formulations. More particularly it is directed to liquid formulations comprising anti-TG2 antibodies and to methods of producing such formulations. The liquid formulations according to the invention are stable upon storage at a temperature from about 2 to 25°C for an appropriate period of time.

WO 2023/067051 A1